Bridgefront Capital LLC Acquires New Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Bridgefront Capital LLC acquired a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,475 shares of the company’s stock, valued at approximately $63,000.

Several other hedge funds also recently bought and sold shares of SANA. State Street Corp grew its stake in Sana Biotechnology by 102.2% during the first quarter. State Street Corp now owns 7,150,930 shares of the company’s stock valued at $59,067,000 after acquiring an additional 3,614,591 shares in the last quarter. Alphabet Inc. bought a new stake in Sana Biotechnology during the third quarter valued at approximately $16,875,000. Public Sector Pension Investment Board lifted its position in Sana Biotechnology by 54.9% during the second quarter. Public Sector Pension Investment Board now owns 6,400,000 shares of the company’s stock valued at $41,152,000 after purchasing an additional 2,268,751 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Sana Biotechnology by 41.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 2,891,581 shares of the company’s stock valued at $18,593,000 after purchasing an additional 841,448 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Sana Biotechnology by 9.8% during the third quarter. Vanguard Group Inc. now owns 8,839,881 shares of the company’s stock valued at $53,040,000 after purchasing an additional 787,470 shares during the last quarter. Hedge funds and other institutional investors own 67.12% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley dropped their target price on shares of Sana Biotechnology from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, January 24th.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.50 on Friday. The firm has a market cap of $667.56 million, a PE ratio of -2.17 and a beta of 0.65. Sana Biotechnology, Inc. has a 1 year low of $2.99 and a 1 year high of $9.60. The company has a 50 day simple moving average of $4.18 and a two-hundred day simple moving average of $4.86.

Insider Transactions at Sana Biotechnology

In other Sana Biotechnology news, Director Joshua H. Bilenker acquired 20,000 shares of the stock in a transaction dated Friday, February 3rd. The stock was purchased at an average cost of $25.00 per share, for a total transaction of $500,000.00. Following the acquisition, the director now owns 20,000 shares in the company, valued at approximately $500,000. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 35.40% of the company’s stock.

About Sana Biotechnology

(Get Rating)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.